DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20181649

Efficacy and safety of prucalopride in the treatment of chronic constipation

Anand R. Kanaki, Asharani A. Kanaki, Sharanabasappa Singanal

Abstract


Background: Chronic constipation is a common condition that significantly impacts health care utilization, productivity, and quality of life. Laxatives are commonly used, although often insufficient in restoring normal bowel function or providing adequate relief. There remains a significant need for the development of novel agents to optimize treatment of this condition. Prucalopride, a selective, high-affinity 5-hydroxytryptamine 4 receptor agonist, stimulates gastrointestinal and colonic motility and alleviates common symptoms of chronic constipation. Here authors are evaluating efficacy and safety study of this drug in chronic constipation patient.

Methods: This is a prospective observational study where chronic constipation patient treated with prucalopride 2 mg daily once were enrolled during 6 month period. Data at one week and four weeks were observed along with adverse effects. Efficacy assessed by the number of Spontaneous Complete Bowel Movements (SCBMs) per week recorded by patient diaries. Patients were defined as responders when they had a mean of three or more SCBMs per week over the whole treatment period. The primary efficacy end point was proportion of responders after 1 week and after 4 weeks of treatment.

Results: A total of 43 patients diagnosed with chronic constipation and treated with prucalopride were included in study. The proportions of patients in the present study with at least three SCBMs per week (responders) were 44.2% (19 out of 43 patients) at 1 week and 46.5% (20 out of 43 patients) at 4 weeks. Treatment was well tolerated with minimal side effects. Common adverse effects reported in our study were gastrointestinal disorders like diarrhea, nausea and abdominal pain and nervous system disorders like headache and dizziness.

Conclusions: Prucalopride is effective, has a good safety profile, and is well tolerated in chronic constipation treatment.


Keywords


Chronic constipation, Prucalopride, Responders

Full Text:

PDF

References


Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608.

Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation: a different entity for patients and doctors. Family practice. 1996 Jan 1;13(2):156-9.

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr 1;130(5):1480-91.

Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582-91.

Wald A, Scarpignato C, Mueller‐Lissner S, Kamm MA, Hinkel U, Helfrich I, et al. A multinational survey of prevalence and patterns of laxative use among adults with self‐defined constipation. Alimentary pharmacology & therapeutics. 2008 Oct 1;28(7):917-30.

Prevalence of constipation among the general population: a community-based survey from India. Rajput M, Saini SK. Gastroenterol Nurs. 2014 Nov-Dec;37(6):425-9.

Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. The American J of Gastroenterology. 2005 Jan;100(1):232.

Vazquez Roque M, Bouras EP. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;10:919-30.

Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608.

Jiang C, Xu Q, Wen X, Sun H. Current developments in pharmacological therapeutics for chronic constipation. Acta Pharm Sin B. 2015;5(4):300-9.

De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99-112.

Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Heylen L, Leysen JE, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. European journal of pharmacology. 2001 Jun 29;423(1):71-83.

Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12‐week, randomized, double‐blind, placebo‐controlled study. Alimentary Pharmacology & Therapeutics. 2009 Feb 1;29(3):315-28.

Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. New England Journal of Medicine. 2008 May 29;358(22):2344-54.

Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R. Effect of prucalopride on symptoms of chronic constipation. Neuro gastroenterology & Motility. 2014 Jan 1;26(1):21-7.

Yiannakou Y, Piessevaux H, Bouchoucha M, Schiefke I, Filip R, Gabalec L, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. The American journal of gastroenterology. 2015 May;110(5):741.

Müller‐lissner S, Rykx A, Kerstens R, Vandeplassche L. A double‐blind, placebo‐controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterology & Motility. 2010 Sep 1;22(9):991.

Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. The American journal of gastroenterology. 2014 Jun;109(6):887.

Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Alimentary pharmacology & therapeutics. 2014 Feb 1;39(3):239-53.

Mendzelevski B, Ausma J, Chanter DO, Robinson P, Kerstens R, Vandeplassche L, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double‐blind, placebo‐and positive‐controlled thorough QT study. British journal of clinical pharmacology. 2012 Feb 1;73(2):203-9.